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Abstract
The long running controversy about the relative merits of hazard-based versus risk-based approaches has been investigated. 
There are three levels of hazard codification: level 1 divides chemicals into dichotomous bands of hazardous and non-haz-
ardous; level 2 divides chemicals into bands of hazard based on severity and/or potency; and level 3 places each chemical on 
a continuum of hazard based on severity and/or potency. Any system which imposes compartments onto a continuum will 
give rise to issues at the boundaries, especially with only two compartments. Level 1 schemes are only justifiable if there is 
no variation in severity, or potency or if there is no threshold. This is the assumption implicit in GHS/EU classification for 
carcinogenicity, reproductive toxicity and mutagenicity. However, this assumption has been challenged. Codification level 
2 hazard assessments offer a range of choices and reduce the built-in conflict inherent in the level 1 process. Level 3 assess-
ments allow a full range of choices between the extremes and reduce the built-in conflict even more. The underlying reason 
for the controversy between hazard and risk is the use of level 1 hazard codification schemes in situations where there are 
ranges of severity and potency which require the use of level 2 or level 3 hazard codification. There is not a major difference 
between level 2 and level 3 codification, and they can both be used to select appropriate risk management options. Existing 
level 1 codification schemes should be reviewed and developed into level 2 schemes where appropriate.
Abbreviations
CLP  Classification, labelling, and packaging
ED10  Dose calculated to induce effects with an inci-
dence or magnitude of 10% effect level above 
background data
EU  European Union
GHS  Global harmonisation system of classification and 
labelling of chemicals
IARC  International Agency for Research on Cancer
MOA  Mode of action
T25  The chronic daily dose in mg per kg bodyweight 
which will give 25% of the animals tumours at a 
specific tissue site, after correction for spontane-
ous incidence, within the standard life span of that 
species
Introduction
There has been a long running controversy about the rela-
tive merits of hazard-based versus risk-based approaches in 
managing the potential for harm to human health from the 
use of chemicals. Lofsted (2011) in his article ‘Risk versus 
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Hazard—How to Regulate in the 21st Century’ outlined the 
issues involved. These included inconsistency in approach 
where countries use hazard-based legislation to ban chemi-
cals of no consequence to their economy and risk-based leg-
islation to keep the chemicals that matter to them. This can 
result in inappropriate levels of concern, either too much or 
too little, over some chemicals due to factors such as percep-
tion of no choice in exposure, poorly understood technical 
issues such as dose response, unfamiliarity with uses and 
benefits, and political desire to ban or to keep in use. The 
resultant controversy was expressed in the question “Should 
regulations be based on a hazard classification (that is the 
potential for a substance, activity or process to cause harm 
or adverse effect) or a risk (a combination of the likelihood 
and the severity of a substance, activity or process to cause 
harm) assessment?” (Lofsted 2011). Recently, the German 
Federal Institute for Risk Assessment (BfR) (Herzler et al. 
2021) expressed concerns over the EU chemical strategy, 
including the intention to move away from a risk-based to 
a hazard-based assessment paradigm. They said that “such 
a move, tempting as it might be, is bound to create a range 
of problems and will likely result in a system that by design 
would be inherently arbitrary and inconsistent”.
In a previous paper (Boobis et al. 2016), we highlighted 
the issues arising from classification for cancer by hazard 
identification rather than by hazard characterization which 
results in chemicals in the same category with up to seven 
orders of magnitude difference in potency that causes confu-
sion and makes it difficult to make sound decisions on risk 
management. In this paper, we explore how the complexities 
of the output from toxicological studies are simplified and 
codified before being used in regulatory schemes not only 
for cancer but for other areas such as reproductive toxicity, 
endocrine disruption, and mutagenicity. We conclude that 
the risk versus hazard controversy is fueled by the use of 
over simplistic binary classification schemes and that there 
are ways forward within the existing schemes which could 
avoid this problem.
Hazard codification and the regulation 
of chemicals
The aim of chemical regulation is to minimize the risk of 
ill health caused by exposure to chemicals. To do this, the 
capability of a chemical to cause harm has to be known and 
compared with the measured or estimated human exposure. 
Whether a hazard-based system or a risk-based system is 
used, the hazard must be understood sufficiently to allow a 
choice among risk management options aimed at minimizing 
adverse effects on public health. This understanding must be 
both qualitative—what could it do—and quantitative—how 
much is needed to do it.
The term "hazardous chemical” is widely used in the EU 
chemical safety approach, with the policy aim to avoid expo-
sures to "hazardous chemicals” and to replace them with 
less hazardous ones. A European Parliament resolution (EU 
2020a) states that “the chemical, physical and toxicological 
properties of chemicals vary greatly” and that “a transition is 
needed towards producing chemicals that are safe by design, 
including using less hazardous chemicals”. This policy 
opens up the question of what is a ‘hazardous chemical’, 
and how would it differ from a ‘less hazardous chemical’.
There are two aspects to hazard: the adverse effects the 
chemical has the potential to cause; and the circumstances 
(including dose level, duration and route of exposure) in 
which it might cause them. These components of the degree 
of hazard are generally known as severity and potency. 
Clearly, there is a difference in severity between a mild tran-
sient effect such as skin reddening and a life-threatening 
progressive disease such as cancer. Equally, there are differ-
ences in potency between chemicals showing effects only at 
high doses such as grams/kg and those which cause effects 
at low doses such as µg/kg. There is a continuum of potency 
and a continuum of severity, albeit potency is easier to quan-
tify than severity.
The GHS scheme takes into account a third aspect of the 
toxicity of a chemical in determining its hazard classifica-
tion, that of mode of action (MOA) (United Nations 2019). 
The effects of a chemical at high doses may be dependent 
on an MOA different from that occurring at exposures even 
remotely possible in human populations, or it may be that 
the MOA for an effect is not relevant to humans due to fun-
damental qualitative differences in biology. In such cases, 
GHS takes this into account in a decision on classification, 
although this is not carried through into the EU scheme 
based on GHS.
If hazard is defined as the potential to cause harm and the 
toxicological properties of chemicals vary greatly, then each 
chemical has a combination of severity and potency which 
determine how hazardous it is. Thus, it is important to be 
able to quantify the ‘degree of hazard’ (a term used in EU 
Classification, Packaging and Labelling guidance, ECHA 
2017) which a chemical may pose, so that appropriate risk 
management measures can be taken.
A full toxicological evaluation of a chemical generates 
thousands of pieces of information which detail the type of 
effects and the doses at which they occur. This information 
must be assessed for quality and reliability, as well as sum-
marised and codified before it can be used for safety deci-
sion-making. We put forward the concept that there are three 
main levels of codification at which this is done (Table 1):
Codification levels 1 and 2 are used in classification 
schemes and level 3 is used in risk assessment schemes. 
Level 1 is binary and uses a weight of evidence approach to 
determine if a chemical has the potential to cause a particular 
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class of adverse effect, although, in practice, strength of evi-
dence is frequently used. If the chemical is considered to 
have the potential to cause an effect, then it is deemed to be 
‘hazardous’ and if it is considered not to have the potential it 
is deemed to be ‘not hazardous’. Within this type of scheme, 
all the chemicals deemed to be hazardous are considered as 
if they have the same severity and potency of effect. Level 
1 schemes are applied to carcinogenicity, mutagenicity, and 
reproductive toxicity (CMR) within the EU/GHS scheme 
(ECHA 2017). Risk management decisions are then taken 
based on the assumption of the same severity and potency. 
The risk management decisions also tend to be binary, i.e., 
ban or allow over broad areas of use. It is not possible to 
balance alternate risks, provide multiple options, or tar-
geted mitigation strategies. The problems associated with 
this approach have been described by Boobis et al. (2016).
Level 2 uses a discontinuous variable weight of evi-
dence (WOE) approach to consider severity and potency. 
In some cases, such as dermal and eye irritation, the dose 
is fixed and the severity of the response is graded to deter-
mine the compartment within the class that is appropriate 
for the chemical. In other cases, such as acute lethality, the 
end point is fixed and the compartmentalization is decided 
on the potency. Specific target organ toxicity is an example 
of a level 2 scheme within CLP (ECHA 2017) that uses a 
combination of severity and potency to determine which 
compartment the chemical fits within. First, the chemical 
must show ‘significant’ or ‘severe’ toxicity. In this con-
text, ‘significant’ apparently means “changes which clearly 
indicate functional disturbance or morphological changes 
which are toxicologically relevant. ‘Severe’ effects are 
generally more profound or serious than ‘significant’ 
effects and are of a considerably adverse nature which 
significantly impact health”. Then, the point of departure 
is used to assign the chemical to one of three categories. 
This enables a greater range of risk management options 
than with a level 1 scheme, because the compartments are 
based on severity and/or potency and the use of the same 
principles for developing a level 2 scheme for CMR will 
be explored in this paper.
Level 3 uses a continuous variable approach to incorpo-
rate a combination of severity and potency to derive doses 
which are of no or low concern. Potency is considered by 
examining the dose–response curve and determining the 
dose at which no or minimal effect is expected (point of 
departure) to which a safety/uncertainty factor is applied 
(Dorne et al. 2005; Dourson and Stara 1983; Dourson and 
Felter 1996) or by other means such as low-dose extrapola-
tion to a low probability of effect. Severity, at times, drives 
the size of the safety factor that is considered necessary to 
ensure safety. This may be done by applying an additional 
factor to the point of departure if the effect is deemed to be 
severe (e.g., developmental abnormalities), although this 
does not apply in all regulatory frameworks that consider 
adequacy of available data and not severity of a particu-
lar effect (Dourson and Felter 1996). Each chemical is 
considered on the basis of the available toxicological and 
exposure evidence, and risk management options can be 
specifically designed for the situation.
To summarise:
• Codification Level 1 attempts to divide chemicals into 
the dichotomous bands of hazardous and non-hazard-
ous. It does not allow for degree of hazard.
• Codification Level 2 divides chemicals into a number 
of bands to accommodate different degrees of hazard 
based on severity of effects and/or potency of the agent.




Summary Risk management options
Level 1 Presence or absence of a class of adverse effect
Yes or no binary choice (limited banding)
Restricts risk management and assumes all chemicals have the same severity/
potency
No flexibility
Level 2 Compartmentalization of hazard first by nature 
of adverse effect and then by potency by 
banding with several categories (typically 
3–5)
Semi-quantitative
Provides more risk management choices that reflect differences in severity/
potency
Some flexibility
Useful when data are limited
Level 3 Description of nature of adverse effect and the 
derivation of a health based guidance value 
(e.g., acceptable daily intake, reference dose, 
derived no effect level) to establish safe levels 
of exposure
Infinite bands, continuous response based on 
quantitative dose response risk assessment
Broad range of risk management options
Maximizes flexibility and accuracy for a more reliable fit for purpose assessment
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• Codification Level 3 places each chemical on a con-
tinuum of degree of hazard based on severity and/or 
potency.
Based on the codification level scheme we have devel-
oped, it can be seen that the GHS/CLP classification system 
uses both Level 1 and Level 2 hazard codification. Level 2 
codification is used for acute lethality, dermal and eye irrita-
tion/corrosivity, dermal sensitization, and single exposure 
and repeat exposure-specific target organ toxicity. Level 1 
codification is used for mutagenicity, carcinogenicity, devel-
opmental, and reproductive toxicity. Level 1 codification has 
also been introduced in the EU not only for a specific effect 
but also for a mode of action, endocrine disruption (EU 
2018a, b, 2020b). In addition, it has been suggested that 
Level 1 coding should be expanded to immunotoxicity and 
neurotoxicity (EU 2020a). The rationale for expanding the 
use of Level 1 codification processes has not been scientifi-
cally justified, and therefore, it would not be appropriate to 
use them given their inherent limitations.
Leaving aside political concerns, the only scientific justi-
fication for Level 1 codification of hazard is if it is not pos-
sible to identify exposure levels that would not cause some 
harm. In this situation, all chemicals that have the potential 
to express the hazard would be considered equally hazard-
ous and treated as if they have similar severity and similar 
potency. All such chemicals would, therefore, be subjected 
to the same risk management procedures. We have examined 
the schemes where Level 1 codification is used to determine 
whether this assumption is justifiable or whether there is a 
range of hazard that could reasonably be based on severity, 
potency, and mode of action which would mean that the 
assumption is not appropriate.
Carcinogenicity
There is a wide range of potency for the induction of 
tumours in long-term rodent bioassays; EU CLP (ECHA 
2017) guidelines state: “Experimental studies have 
revealed large variations in the doses of various carcino-
genic substances needed to induce tumours in animals. 
Thus, the amounts of a chemical carcinogens required to 
induce tumours vary with a factor of up to  109 for differ-
ent compounds. It is reasonable to assume that there is 
similar variation in the potency of substances carcinogenic 
to humans (Sanner and Dybing 2005)”. Clearly, there is a 
continuum of potency and it is inappropriate to ignore this 
in hazard codification. The question of whether there is a 
range of severity in cancer is less easy to address. In most 
areas of toxicity, there is an increase in both the incidence 
and the severity of adverse effects with increasing dose. 
In long-term rodent bioassays, the number of neoplasms 
in the treated groups is compared with the control group. 
Although there is often a progression of histopathologi-
cal observations such as hyperplasia leading to neoplasia, 
and there may be debate about where the dividing line 
between the two should be placed, once a neoplasm has 
been observed it is added to the tally. Currently, no dis-
tinction in hazard for chemicals (non-pharmaceuticals) 
is made between benign and malignant tumours. There 
is certainly a difference in mode of action, and for most 
carcinogenic effects, there is an obligatory progression 
from reversible toxicity to neoplasia, so that that health 
protective risk management can be based on minimizing 
the precursor toxic effects.
At first glance, it appears that the GHS/EU CLP and the 
IARC classification systems employ Level 2 hazard codifica-
tion. GHS/EU CLP has Category 1 and Category 2. IARC 
has Groups 1–3 (previously 4). However, inspection of the 
schemes reveals that the category or group relates to the 
strength of evidence that the chemical is or is not a carcino-
gen and does not take into account its severity (magnitude 
of tumour response) or potency (dose needed to initiate and 
promote carcinogenicity) or mode of action.
In fact, IARC’s grouping is based on the strength of evi-
dence as to whether the hazard is possible not on degree of 
hazard (IARC 2019):
Group 1: the agent is carcinogenic to humans.
Group 2A: the agent is probably carcinogenic to humans.
Group 2B: the agent is possibly carcinogenic to humans.
Group 3: the agent is not classifiable as to its carcino-
genicity to humans.
The assessment is at Level 1, and this has been confirmed 
in the change to the name of the IARC monograph pro-
gramme in 2019 when ‘Evaluation of Carcinogenic Risks’ 
became ‘Identification of Carcinogenic Hazards’. IARC 
emphasises the point that they are operating Level 1 hazard 
codification: “The categories of the classification refer to 
the strength of the evidence that an exposure is carcinogenic 
and not to the risk of cancer from particular exposures. The 
terms ‘probably carcinogenic’ and ‘possibly carcinogenic’ 
have no quantitative significance and are used as descrip-
tors of different strengths of evidence of carcinogenicity in 
humans; ‘probably carcinogenic’ signifies a greater strength 
of evidence than ‘possibly carcinogenic’.”
It is not as immediately apparent that the EU/GHS CLP 
is a Level 1 scheme. Category 1 is for chemicals known (1A 
from human evidence) or presumed (1B from animal evi-
dence) to have carcinogenic potential for humans based on 
the strength of evidence. Chemicals are placed in Category 2 
on similar evidence “but which is not sufficiently convincing 
to place the substance in Category 1A or 1B”. This implies 
that the hazard codification is at Level 1, binary carcino-
gen/non-carcinogen. The different categories do not reflect 
the degree of hazard (severity/potency), but the strength of 
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evidence that the hazard is possible thus making it difficult 
to link risk management choices to the categorisation.
The guidance in the EU (2017) seems to be less certain. 
The commentary seems to mix up strength of evidence with 
weight of evidence in terms of severity and potency. For 
instance, in referring to evidence from 2-year bioassays the 
guidance says: “In general, chemicals are evaluated for car-
cinogenic potential in two-year bioassays conducted in mice 
and rats. The chemicals produce a spectrum of responses 
ranging from no effects in either species to induction of 
malignant neoplasms in multiple tissues in both species. 
Between these two extremes, there are variable responses 
in tissues, sexes, and species which demonstrate that there 
are important differences among the carcinogens, as well as 
between the species in which they are tested. The tumour 
profile observed with a substance should be taken into 
account when considering the most appropriate classifica-
tion. Evidence shows that substances which cause tumours 
in either multiple sites and/or multiple species tend to be 
more potent carcinogens (emphasis added) than those caus-
ing tumours at only one site in one species (Dybing et al. 
1997). This is often true for substances which are mutagenic. 
Also, where human carcinogens have been tested in two or 
more species, the majority have caused cancer in several 
species (Tennant 1993). Thus, if a substance causes tumours 
at multiple sites and/or in more than one species then this 
usually provides strong evidence of carcinogenicity (empha-
sis added). Typically, such a tumour profile would lead to a 
classification in category 1B”.
This may imply that Category 1 is for ‘more potent car-
cinogens’  and by default Category 2 is for ‘less potent car-
cinogens’. The concept that Category 2 should be for ‘less 
potent carcinogens’  is also indirectly implied in the guid-
ance for consideration of malignant and benign tumours: “In 
general, if a substance involves a treatment related increase 
in tumours then it will meet the criteria for classification as a 
carcinogen. If the substance has been shown to cause malig-
nant tumours this will usually constitute sufficient evidence 
of carcinogenicity supporting Category 1B. The induction 
of only benign tumours usually provides a lower strength of 
evidence for carcinogenicity than the induction of malignant 
tumours and will usually support Category 2”.
This clearly shows the problem of level 1 hazard codi-
fication which cannot accommodate the ‘important differ-
ences among the carcinogens’ which is stated in the EU 
CLP Guidance. The guidance also makes the point that 
“in stochastic phenomena the incidence but not severity 
increases with dose, whereas in threshold toxicity both 
incidence and severity usually increase with dose”. The 
induction of cancer can be both stochastic and threshold 
depending on the mode of action (US EPA 2005 Can-
cer Guidelines; Wolf et al. 2019). As such, both sever-
ity and incidence can increase with dose, and for some 
carcinogens, it is possible to identify exposure levels 
below which there is no toxicological concern. This under-
lines that Level 1 hazard codification is not scientifically 
justifiable nor appropriate for use to address carcinogenic-
ity potential.
The EU (ECHA 2017) acknowledges the problem created 
by the Level 1 codification for carcinogenicity in the way 
limits are created for the presence of categorised chemicals 
in commercial preparations. The guidance contains provi-
sions for what are called Specific Concentration Limits; 
these set out the maximum concentration of a substance 
which can be used in a product based on its classification. 
The more severe the category, the lower the Specific Con-
centration Limits. This works for Level 2 hazard codifica-
tions which take into account severity and potency. Lower 
limits are set for the more potent substances. However, Level 
1 codification hazard categories cause problems, because the 
potency is not reflected in the category.
This was addressed by an expert working group 
(EC 1999) which pointed out the following: “However, the 
general classification system for carcinogens does not take 
into account the wide range of carcinogenic potency that 
can be observed both in human epidemiological studies and 
in animal experiments. As well as the need for a system to 
reflect this wide range of carcinogen potencies, there are 
examples of carcinogens where the question of potency as 
such is of particular concern.”
“In some cases, it is the high potency of the sub-
stances such as dimethylsulfate and hexylmethylphos-
phoramide or impurities such as TCDD and certain 
nitrosamines which gives rise to concern and it is pos-
sible that a general limit of 0.1% does not adequately 
express the hazard. In other cases, substances may be 
classified as carcinogens although relatively high doses 
are needed to induce tumours. In such cases the gen-
eral limit may not adequately express the hazard of a 
preparation containing such substances, this time by 
over-estimating the carcinogenicity of the preparation. 
Other intrinsic properties of chemical carcinogens may 
contribute to overall concern, such as the induction of 
tumours after a very short latency period, or the occur-
rence of tumours in many different tissue sites. This 
may be addressed by assigning lower specific con-
centration limits for such substances, if not addressed 
directly by the classification.”
The expert working group (EC 1999) pointed out the 
limitations of the Level 1 hazard codification system and 
went about developing a Level 2 hazard codification scheme. 
They reviewed the measures of potency which have been 
used and decided on the T25 value as it can be calculated in 
most cases. They used it to place substances classified as a 
carcinogen into ranges that define potency.
 Archives of Toxicology
1 3
• Carcinogens of high potency: T25 value < 1 mg/kg body-
weight/day.
• Carcinogens of medium potency: 1 mg/kg bodyweight/
day < T25 value < 100 mg/kg bodyweight/day.
• Carcinogens of low potency: T25 value > 100 mg/kg 
bodyweight/day.
The leading principle used for deriving the 1 and 100 mg/
kg bodyweight/day limits was the distribution of values in 
the database from Gold et al. (1989) with the majority of 
carcinogens falling into the medium potency range.
The expert group then went on to define modifying fac-
tors that could affect the level of concern including the 
dose–response curve, the site/species/sex incidence of 
tumours, mode of action including genotoxicity, and human 
relevance. They describe how these factors can be used 
to modify the initial categorisation based on potency. For 
instance, a genotoxic mode of action would indicate move-
ment to a higher potency group. Lack of human relevance 
would indicate movement to a lower potency group. Overall, 
they described a process to assign chemicals that have been 
shown to cause cancer to one of three categories based on 
potency and severity; in other words, they describe a Level 
2 hazard codification scheme. At present, the Level 2 hazard 
codification scheme is only used to set Specific Concentra-
tion Limits, but it represents a ready-made solution to the 
problems caused by the Level 1 hazard codification GHS/
EU classification scheme.
Reproductive and developmental toxicity
It is appropriate to consider reproductive toxicity (effects 
on the fertility and sexual function) and developmental tox-
icity (effects on the developing offspring) separately from 
each other. There is a range of severity of effect on repro-
ductive toxicity from reversible small changes in gonadal 
histopathology and fertility to an irreversible and complete 
absence of fertility. Some effects identified in the reproduc-
tive system from a standard OECD test guideline study, 
while measurable, have no impact on fertility and fecundity 
and thus have questionable relevance for hazard identifica-
tion. The EU commissioned a study to determine the rela-
tive potency of substances in causing reproductive toxic-
ity and to recommend ways of assessing potency (Muller 
et al. 2012). They created databases for substances that are 
classified for reproductive toxicity in the EU for effects on 
reproduction and fertility and for developmental toxicity. 
The potency range of substances in the database was a fac-
tor of approximately six orders of magnitude, similar to the 
range of potency for carcinogenicity (Sanner and Dybing 
2005). Adverse effects on fertility and sexual function of a 
substance can differ between dose levels from small changes 
in testes histopathology through effects on fertility to an irre-
versible and complete absence of fertility. Reduced fertility 
or irreversible changes in reproductive organs would be con-
sidered of high concern, whereas minor, reversible changes 
in histopathology or weight of reproductive organ would be 
considered of low concern.
There is clearly a continuum of severity and potency for 
reproductive toxicity, indicating that there is a wide varia-
tion in the degrees of hazard in chemicals which have the 
potential to cause reproductive toxicity.
Developmental toxicity studies categorise adverse effects 
that are irreversible, such as malformations and abnormali-
ties, to be more severe, while a lower level of concern is 
given to variations and retardations such as delayed ossi-
fication, wavy ribs, and other minor skeletal variations 
(Carney and Kimmel 2007; Chernoff et al. 1991; Rogers 
et al. 2004). Similarly, minor delays in growth rate or devel-
opmental landmarks would be considered of low concern, 
whereas reduced survival would be considered of high level. 
Functional changes, where assessed, which are not reversed 
during development would be considered more severe than 
functional changes which are observed early in post-natal 
development but later reverse or have no impact on the life 
of the animal. Muller et al. (2012) found that the range of 
potency values for developmental toxicity, like reproductive 
toxicity, also covered six orders of magnitude.
Piersma et al. 2011 examined all the endpoints assessed 
in reproductive and developmental toxicity and found that 
they have thresholds of adversity, therefore providing evi-
dence for the presence of dose levels with no measurable 
adverse effects. It is clearly inappropriate to apply Level 1 
hazard codification to reproductive and developmental toxic-
ity as there are different levels of severity, different modes of 
action, and a large range of potencies and thresholds below 
which there are no adverse effects. Reproductive and devel-
opmental toxicity should be codified at Level 2 or 3 as the 
situation requires.
The Level 1 codification scheme for reproductive and 
developmental toxicity causes the same problems in setting 
Specific Concentration Limits as were described for carci-
nogenicity. Again, the EU commissioned a review of these 
difficulties and a similar approach was taken. On the basis of 
a review by Muller et al. (2012), a potency estimate of ED10 
(dose causing an increase of 10% over control values) was 
used to derive three potency groups:
• High potency group ED10 value ≤ 4 mg/kg bw/day
• Medium potency group 4  mg/kg bw/day < ED10 
value < 400 mg/kg bw/day
• Low potency group ED10 value 400 mg/kg bw/day.
Once the potency group has been determined, the data on 
the chemical are reviewed for other factors that may modify 
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the initial potency determination. The modifying factors 
include the type of effect and its severity, dose–response 
relationship, and mode or mechanism of action. In this way, 
the chemical is assigned to one of three groups based on 
potency and severity, and in other words, this is a Level 2 
hazard codification scheme within the EU CLP guidance. 
At present, this is used only to set Specific Concentration 
Limits, but it could also be applied to the overall categorisa-
tion process.
Mutagenicity
Classification for mutagenicity within the EU/GHS CLP 
(ECHA 2017) scheme is for germ cell mutagenicity, 
although this is sometimes overlooked or misunderstood. 
However, within the scheme, classification as a germ cell 
mutagen has implications for potential carcinogenicity clas-
sification, as all germ cell mutagens are presumed to also 
be somatic cell mutagens (ECHA 2017). Although the con-
cept is being challenged, mutagenicity has been assumed 
to be a quantal effect, present or not present, with a linear 
dose response with no threshold. The EU/GHS CLP (ECHA 
2017) classification system reflects this with Level 1 codifi-
cation with two categories based on the WOE of the chemi-
cal being able to induce heritable mutations in germ cells. 
Category 1A is reserved for chemicals for which there is evi-
dence from humans, and category 1B is based on evidence 
from in vivo assays based on germ cell mutation. Mutations 
in somatic cell in vivo assays are given less weight and point 
towards Category 2, with the assumption that the capability 
to cause mutations in somatic cells is evidence that muta-
tions could be caused in germ cells. Dose responses in germ 
cell and somatic cell assays are not taken into account in the 
weight of evidence evaluation. Indeed, they are specifically 
discounted, as substances that are incapable of causing herit-
able mutations, because they cannot reach the germ cells due 
to physicochemical or pharmacokinetic factors with posi-
tive results in vitro, supported by at least one positive local 
in vivo, somatic cell test for mutagenicity, are classified as 
Category 2, “Substances which cause concern for humans 
owing to the possibility that they may induce heritable muta-
tions in the germ cells of humans”. Category 1A and 1B 
receive the hazard statement ‘May cause genetic defects’ 
and Category 2 receives the hazard statement ‘Suspected of 
causing genetic defects’. Genetic defects comprise heritable 
genetic damage as well as somatic cell mutagenicity.
The GHS process is clearly a Level 1 hazard codification, 
with all chemicals considered to have equal concerns over 
severity and potency. The no-threshold assumption for geno-
toxicity has been challenged for many years, with emphasis 
being placed on the need to consider the mode of action; 
for instance, if genotoxic damage results from damage to 
proteins involved in cell division, like tubulin, there is a 
threshold dose for such genotoxic effects (Zito 2001). Wills 
et al. (2015, 2016) investigated whether there were differ-
ences in potency from the results of in vitro micronucleus 
assays and in vivo genotoxicity assays including the rat 
Pig-a assay and the induction of lacZ transgene mutations 
in Muta™Mouse. They noted that genotoxicity tests have 
traditionally been used only for hazard identification, with 
qualitative dichotomous groupings being used to identify 
compounds that have the capacity to induce mutations and/
or cytogenetic alterations (i.e., Level 1 hazard codifica-
tion). Wills et al. were interested in determining whether 
they could use estimates of potency using dose–response 
data to derive point of departure metrics that could be used 
to establish human exposure limits or margins of exposure 
(MOEs), thereby supporting human health risk assessments 
and regulatory decisions. They concluded that the results 
of the assays could be used for more than hazard identi-
fication. More specifically, they illustrate that quantitative 
robust potency determinations and potency rankings can be 
made. Others (MacGregor et al. 2015a, 2015b; Clewell and 
Anderson 2016; Long et al. 2018; Metruccio and Moretto 
2018) have reached similar conclusions. In addition, qual-
itative information on modes of action and the nature of 
dose–response relationships for different types of mutagenic 
response has revealed that there are clear, mechanistically 
explicable thresholds (Muller et al. 2009, Kirsch-Volders 
et al. 2009, Gollapudi 2017; Gollapudi et al. 2013). It is 
now time for serious consideration of Level 2 and 3 hazard 
codification schemes for mutagenicity by those classifying 
and risk assessing chemicals.
Endocrine disruption
Endocrine disruption has been designated in the EU as a 
separate hazard. This is unique in being an MOA-based haz-
ard categorization rather than hazard based on observation 
of adverse effects. A chemical can be designated to have 
endocrine disrupting properties if it meets the following 
conditions:
(a) It shows an adverse effect in an intact organism or its 
progeny.
(b) It has an endocrine MOA, i.e., it alters the function(s) 
of the endocrine system.
(c) The adverse effect is a consequence of the endocrine 
MOA.
All three conditions must be met, and a guidance docu-
ment has been published for how to evaluate data to deter-
mine whether a chemical should be classified (EU 2018a). 
However, there are suggestions that classification could also 
be based on suspicion of endocrine disrupting activity (EU 
2020b).
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Classification for endocrine disruption is based on hazard 
identification only, severity and potency are not considered, 
and it is therefore a Level 1 hazard codification system. This 
is linked to mandated severe risk management for pesticides 
and biocides, and there are regulatory moves to extend it 
to other chemical categories. Once a biocide or pesticide 
has been classified as an endocrine disruptor, the chemical 
cannot be authorised for any use. The reason given is that 
scientific uncertainty remains regarding their assessment [for 
example as regards the existence of a safe limit of exposure 
(EU, 2018b)]. This contradicts EFSA’s Scientific Commit-
tee, which concluded that biological thresholds of adver-
sity do exist and considered human and environmental risk 
assessment (taking into account hazard and exposure data/
predictions) the best approach to inform risk management 
decisions in regulations that base decisions on the risk and 
level of concern (EU 2020b). According to EFSA’s Scientific 
Committee, “EDs can therefore be treated like most other 
substances of concern for human health and the environ-
ment, i.e. be subject to risk assessment and not only to haz-
ard assessment”. In other words, the EFSA Scientific Com-
mittee recommended the use of a Level 2 or Level 3 hazard 
codification scheme for endocrine disruption. The adverse 
effects resulting from changes in the endocrine system fall 
into the categories of specific organ toxicity, carcinogenicity 
or reproductive toxicity. There are Level 2 hazard codifica-
tion schemes available for all these adverse effects, which 
include consideration of MOA and dose response.
Level 1 codification and the precautionary 
principle
The aim of the precautionary principle, according to an 
EU Parliamentary Review (EU 2017), is “to avoid causing 
adverse impacts in situations of scientific uncertainty”. The 
review contains these definitions:
Hazard: situation or risk that a substance or technol-
ogy, by reason of its inherent characteristics or properties, 
could—under specific conditions of exposure—endanger 
people, property, or the environment.
Risk: likelihood of an adverse event occurring because a 
hazard coincides with exposure to that hazard.
Uncertainty: a situation where environmental and/or 
human health impacts are likely, but the probabilities are 
unknown, may lead to precautionary measures to reduce 
exposure to certain hazards. (Note from authors: the EU 
does not define “likely, but the probabilities are unknown”. 
The phrase could be taken to mean “possible” and there-
fore justify precautionary measures in a wide range of 
circumstances.)
Level 1 hazard codification schemes are applications of 
the precautionary principle. It is understandable that Level 1 
schemes were initially adopted for carcinogenicity, mutagen-
icity, and reproductive toxicity in the early days of chemi-
cal safety evaluation. At that time, MOAs were unknown, 
and dose–response curves were unexplored with concerns 
over whether there were thresholds for some adverse effects. 
This situation met the definition of scientific uncertainty 
where health impacts were likely, but the probabilities were 
unknown and an application of the precautionary principle 
could be justified.
The EU Review then goes on to state that, “Where risks 
are established with certainty, it is the prevention princi-
ple, as enshrined in the Treaty on the Functioning of the 
European Union, which can be brought into play to adopt 
hazard prevention measures.” As the body of knowledge 
about the effects of chemicals increased, the MOAs and 
dose–response curves become defined, and the risks (when 
the hazard coincides with exposure) can be established and 
the prevention principle (taking appropriate action to prevent 
adverse effects) should be applied.
Endocrine disruption provides an example of the evolu-
tion of knowledge. Initially, there were concerns over the 
effects and the dose response being atypical as voiced by the 
some members of the Endocrine Society and they invoked 
the precautionary principle to advocate a level 1 approach 
(Diamanti-Kandarakis et al. 2009). The review commis-
sioned by the EU (2018b) gathered all the evidence and 
concluded that biological thresholds of adversity do exist 
and that level 2 and 3 approaches are appropriate for endo-
crine disruption.
Level 2 and 3 codification schemes allow the adoption 
of appropriate prevention measures as required in the pre-
vention principle. Level 1 schemes deprive policymakers of 
essential information necessary for decision-making. The 
precautionary principle could still be invoked for compounds 
codified using a Level 2 or Level 3 scheme, resulting in such 
decisions being better informed with greater scientific rigour 
and justification.
Discussion
The purpose of this paper was to investigate the scientific 
reasons behind the controversy between hazard-based 
and risk-based chemical regulatory and safety assessment 
schemes which was highlighted by Lofsted (2011) and by 
the BfR (2021). Our investigation has revealed that the con-
troversy is not between hazard and risk. It is between Level 
1 hazard codification on one hand and Level 2 and 3 hazard 
codification on the other.
One reason that Level 1 codification creates controversy 
is because it divides substances into only two categories: 
hazardous or non-hazardous. Controversy arises, because the 
fewer the categories, the greater the probability of disputes 
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and the temptation to influence the assignment of a sub-
stance to a predetermined category in either direction. The 
greatest probability of such problems occurs when Level 1 
binary hazardous/non-hazardous hazard codification is used 
to trigger severe risk management decisions such as banning 
of chemicals for broad categories of use. The process can 
become a quasi-forensic exercise where evidence is brought 
in, in a similar way to a legal case, with each side of the 
binary argument amassing evidence to support its precon-
ceived idea. A case in point is the key characteristics of 
carcinogens (Smith et al. 2016), which may provide useful 
information for the understanding of carcinogenic MOAs 
but which should not be used as evidence for or against a 
dichotomous classification. The restrictive nature of a two-
choice scheme creates unnecessary angst in the process of 
chemical regulation.
A second reason Level 1 codification creates controversy 
is because it can create a false dilemma, which is defined 
as when only two choices are presented yet more exist, or a 
spectrum of possible choices exists between two extremes 
(LogicallyFallcious 2021). Other names for a false dilemma 
include all-or-nothing fallacy, either-or reasoning, black-
and-white thinking, and polarization. Clearly, in the case of 
hazards to health posed by chemicals, more than two choices 
exist beyond being hazardous or non-hazardous. We know 
that biological response to chemicals presents a spectrum of 
possible choices between the extremes, and categorization 
schemes should reflect that reality.
Codification Level 2 hazard assessments avoid the Level 
1 bifurcation and false dilemma controversies to some extent 
by offering a limited range of choices between the extremes 
and tend to reduce the built-in conflict inherent in the Level 
1 process. Taking skin irritation as an example, categorising 
a chemical in a Level 1 process as irritating or non-irritating 
would hardly be helpful. However, a Level 2 process allows 
for multiple skin irritation categories that indicate corrosive, 
severe, moderate, and non-irritant, which is easily under-
stood and properly reflects the range of possible outcomes 
from exposure.
Codification Level 3 assessments avoid the false dilemma 
completely by allowing a full range of choices between the 
extremes and reduces the built-in conflict even more. Level 3 
assessments properly reflect the range of biological response 
to chemical substances when sufficient data are generated 
to discern the range. Data that describe the severity and 
potency of an adverse effect should always be used to assess 
the specific use of a chemical.
Level 1 schemes were adopted for carcinogenicity, 
mutagenicity, and reproductive toxicity in the early days 
of chemical safety schemes when modes of action were 
unknown and dose–response curves were unexplored. 
With greater understanding and experience, we now know 
that Level 1 schemes give rise to major problems and led 
to the development of Level 2 hazard codification schemes 
within the EU CLP for carcinogenicity and reproductive 
toxicity. These secondary schemes are only applied for 
setting Specific Concentration Limits and were needed to 
cope with problems resulting from the Level 1 codification 
schemes within which they sit. The studies sponsored by 
the EU to address this problem clearly show that the use 
of Level 1 hazard codification is not scientifically justified 
for carcinogenicity and reproductive toxicity. A pragmatic 
solution to the problem would be to adopt these Level 
2 schemes already in the EU guidelines which take into 
account potency and severity for the categorisation of haz-
ard for carcinogenicity and reproductive toxicity.
The situation is less well studied for mutagenicity, with 
exploration of potency and severity, and of MOAs, and 
their relationship to human safety still being investigated. 
It would be consistent with current scientific understand-
ing of mutagenicity to determine if Level 2 or 3 hazard 
codification schemes could be developed.
It is difficult to see the scientific justification for the 
introduction of a Level 1 hazard codification scheme for 
endocrine disruption in the face of the evidence that, as 
is true for all chemicals and modes of action, there is a 
continuum of biological response. As such, EDs should be 
treated like most other substances of concern for human 
health and the environment with Level 3 risk assessment 
as reflected in an opinion from EFSA (EU 2020b) and not 
add to the false dilemma of a Level 1 hazard assessment.
The use of a Level 1 hazard codification scheme no 
longer provides value in situations where adverse effects 
span ranges of severity and potency when a Level 2 codi-
fication would more properly, and just as easily, categorise 
the range of response. Preferably, Level 3 codification pro-
cesses should be used when data are available to conduct 
a risk assessment. There is not a major conceptual differ-
ence between Level 2 and Level 3 codification, they can 
both be used to select appropriate prevention measures or 
risk management options, although Level 3 may provide 
more precision and less uncertainty. The same laboratory 
animal-based studies are used in each of the three levels. 
Moving away from level 1 binary schemes would not result 
in the use of more animals but would make greater use of 
the information derived from the use of those animals.
In summary, the apparent controversy between haz-
ard-based and risk-based chemical regulatory and safety 
assessment schemes is, in itself, a false dilemma—with 
a twist: determining human health safety does not need 
to rely simply on hazard OR risk, but can be properly 
addressed with data-specific acknowledgement of the 
range of adverse responses possible through the applica-
tion of Level 2 or 3 codifications.
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